BLISS GVS PHARMA LTD
BLISSGVS · General/Diversified · NSE
₹440
Current Market Price
Fair Value (DCF)
₹225
Discount to FV
-48.7%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
62%
ROE
10.8%
Debt/Equity
0.02
WACC
11.1%
Market Cap
₹4,650 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.4%
Return on capital employed
EV / EBITDA
9.7×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
21.3×
EBIT covers interest
Current Ratio
4.81×
Short-term liquidity
Asset Turnover
0.71×
Revenue per ₹ of assets
Revenue CAGR (3Y)
7.4%
3-year revenue growth
Revenue CAGR (5Y)
9.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹439.55
Bear case
Margin of Safety —
Implied upside -258.2%
Base case
Margin of Safety -1917.5%
Implied upside -95.0%
Bull case
Margin of Safety -166.9%
Implied upside -62.5%
Ratio Trends
BLISSGVS · last 10 annual periods
ROE
10.8%
ROCE
19.4%
Operating Margin
—
Debt / Equity
0.02×
PE
17.7×
EV / EBITDA
9.7×
Historical Financials
BLISSGVS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹738 Cr | ₹747 Cr | ₹766 Cr | ₹810 Cr | ₹927 Cr | +5.9% |
| EBITDA | ₹74.4 Cr | ₹128 Cr | ₹149 Cr | ₹163 Cr | ₹235 Cr | +33.3% |
| EBIT | ₹58.9 Cr | ₹116 Cr | ₹124 Cr | — | — | +20.4% |
| PAT | ₹15.0 Cr | ₹70.9 Cr | ₹75.5 Cr | ₹84.3 Cr | ₹129 Cr | +71.2% |
| EPS (diluted) | ₹1.43 | ₹6.72 | ₹7.11 | — | — | +49.3% |
| CFO | ₹135 Cr | ₹34.3 Cr | ₹103 Cr | ₹106 Cr | ₹139 Cr | +0.6% |
| CapEx | ₹-74.0 Cr | ₹-93.8 Cr | ₹-28.3 Cr | ₹-76.3 Cr | ₹-56.8 Cr | — |
| FCF | ₹61.5 Cr | ₹-59.5 Cr | ₹74.5 Cr | ₹29.6 Cr | ₹81.9 Cr | +7.4% |
| Total Assets | ₹1109 Cr | ₹1157 Cr | ₹1212 Cr | ₹1301 Cr | ₹1492 Cr | +7.7% |
| Total Debt | ₹109 Cr | ₹102 Cr | ₹99.8 Cr | ₹88.1 Cr | ₹21.8 Cr | -33.2% |
| Shareholders' Equity | ₹819 Cr | ₹884 Cr | ₹967 Cr | ₹1050 Cr | ₹1193 Cr | +9.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BLISSGVS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 ORCHPHARMA ORCHID PHARMA LIMITED | -144.5%-59.1% upside | 36 | Data Limited | 7.9% | — |
GUJTHEM GUJTHEM | — | — | Pending | 16.2% | — |
 IOLCP IOL CHEM AND PHARMA LTD | -29.2%-22.6% upside | 54 | Above Fair Value | 7.9% | 15.5× |
 GUFICBIO GUFICBIO | — | — | Pending | 9.7% | 42.8× |
 RPGLIFE RPG LIFE SCIENCES LTD | -113.7%-53.2% upside | 40 | Above Fair Value | 20.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹3.00/sh
Last payout
2026-02-18
₹0.50
Peak payout
₹1.00
Trailing yield
0.23%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BLISS GVS PHARMA LTD (BLISSGVS.NS) trades at 439.55 vs a model fair value of 225.36, a gap of -48.7%. Piotroski F-score: 6/9. Moat label:...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BLISSGVS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BLISSGVS →
Compare
Head-to-head with peers
Compare BLISSGVS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BLISSGVSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.